Overview

Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to optimize drug exposure in the target population.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Portola Pharmaceuticals
Collaborator:
Portola Pharmaceuticals
Treatments:
Amiodarone
Betrixaban